Extending our understanding of exenatide: a rare case of angio-oedema
- 18 January 2021
- journal article
- research article
- Published by BMJ in BMJ Case Reports
- Vol. 14 (1) , e235663
Abstract
Exenatide is a subcutaneous injectable glucagon-like peptide 1 receptor agonist that has been approved by the Federal Drug Administration for the treatment of type 2 diabetes mellitus. While side effects such as nausea, vomiting and local hypersensitivity reactions are more commonly described, angio-oedema has never been previously reported in the literature. We present the case of a 67-year-old woman who presented to the emergency department with acute-onset tongue swelling, difficulty breathing, dizziness and diffuse itching which began shortly after receiving her first dose of intramuscular extended release (ER) exenatide. This case aims to raise awareness of the potential adverse effect of angio-oedema secondary to exenatide ER and serves as a reminder to clinicians to discuss possible adverse effects of medications and early recognition of symptoms which would prompt further medical attention.Keywords
This publication has 19 references indexed in Scilit:
- A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyondDrugs in Context, 2015
- Standards of Medical Care in Diabetes—2015 Abridged for Primary Care ProvidersClinical Diabetes, 2015
- Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisDiabetes Technology & Therapeutics, 2015
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label studyThe Lancet, 2013
- Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedemaInternational Journal of Emergency Medicine, 2012
- Clinical relevance of anti‐exenatide antibodies: safety, efficacy and cross‐reactivity with long‐term treatmentDiabetes, Obesity and Metabolism, 2012
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trialThe Lancet, 2010
- AngioedemaWorld Allergy Organization Journal, 2008
- Differential Diagnosis of AngioedemaImmunology and Allergy Clinics of North America, 2006
- AngioedemaClinical Reviews in Allergy & Immunology, 2002